Anke Biotech announced that the company signed the “Exclusive Agency Framework Agreement for CD7-CAR-T and Other Products” on November 11, 2025 to agree on exclusive agency matters in Greater China after PA3-17 injection products are launched. The purpose of this cooperation is to integrate the superior resources of both parties and achieve collaborative development.

Zhitongcaijing · 11/11/2025 10:25
Anke Biotech announced that the company signed the “Exclusive Agency Framework Agreement for CD7-CAR-T and Other Products” on November 11, 2025 to agree on exclusive agency matters in Greater China after PA3-17 injection products are launched. The purpose of this cooperation is to integrate the superior resources of both parties and achieve collaborative development.